Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection

被引:0
|
作者
Vitikainen, Krista [1 ]
Kase, Merit [2 ]
Meriranta, Leo [2 ]
Molander, Pauliina [3 ,4 ]
af Bjorkesten, Clas-Goran [3 ,4 ]
Anttila, Veli-Jukka [4 ,5 ]
Arkkila, Perttu [3 ,4 ]
机构
[1] HUS Helsinki Univ Hosp, Haartmaninkatu 4,POB 340, Helsinki 00029, Finland
[2] HUS Helsinki Univ Hosp, Helsinki, Finland
[3] HUS Helsinki Univ, Abdominal Ctr, Gastroenterol, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
[5] Helsinki Univ Hosp, Dept Infect Dis, Helsinki, Finland
关键词
<italic>Clostridioides difficile</italic>; gastrointestinal infections; inflammatory bowel disease; HEALTH-CARE EPIDEMIOLOGY; HOSPITALIZED-PATIENTS; AMERICA IDSA; GUIDELINES; MANAGEMENT; IMPACT; RISK; DIAGNOSIS; COLECTOMY; COLITIS;
D O I
10.1177/17562848251318292
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Clostridioides difficile infection (CDI) is a clinical challenge associated with poor outcomes in patients with inflammatory bowel disease (IBD).Objectives: To identify clinical risk factors for CDI and its recurrence among patients with IBD.Design: Case-control cohort study of IBD patients with and without episodes of CDI.Methods: A case-control study of 279 IBD patients with CDI. Medical history and IBD-related symptoms 3 months preceding a toxin-positive CDI were recorded and compared with age- and sex-matched IBD patients without CDI. Outcomes of CDI in IBD patients were recorded 2-6 months after CDI.Results: Based on clinical symptoms and fecal calprotectin levels, IBD is active before CDI. Recently diagnosed IBD seemed to increase the risk for CDI. Corticosteroid usage frequently preceded CDI episodes. Advanced therapies were not associated with CDI. Antibiotic intake was not registered before CDI in 30% of the episodes. Recurrent CDI (rCDI) occurred in 30% (84/279) of IBD-CDI patients and 67% (90/135) of those episodes were registered within 90 days from the preceding episode. Most (79%) rCDI patients had ulcerative colitis (UC). CDI could complicate underlying IBD by increasing the need for escalation in IBD-related medical therapy and leading to hospitalization but it did not seem to increase the risk of colectomy.Conclusion: The major risk factors associated with CDI in IBD patients were IBD activity before infection, UC and colonic Crohn's disease, short duration of IBD, corticosteroid usage, and hospitalization. Patients with active IBD and a shorter disease duration may benefit from more frequent follow-ups in the early stages, as they appear to be at higher risk of developing CDI.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Clostridioides Infection in Patients with Inflammatory Bowel Disease
    Lee, Mi Rae
    Kim, Eun Soo
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2022, 80 (02): : 66 - 71
  • [22] Chronic Kidney Disease as a Predictor of Mortality in Hospitalized Inflammatory Bowel Disease Patients With Clostridioides difficile Infection
    Sleiman, Joelle
    Rizvi, Taqi
    Tawfik, Mark
    Qaqish, Faris
    El-Sayegh, Suzanne
    Chalhoub, Jean M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S989 - S989
  • [23] Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease
    Del Vecchio, Livio Enrico
    Fiorani, Marcello
    Tohumcu, Ege
    Bibbo, Stefano
    Porcari, Serena
    Mele, Maria Cristina
    Pizzoferrato, Marco
    Gasbarrini, Antonio
    Cammarota, Giovanni
    Ianiro, Gianluca
    MICROORGANISMS, 2022, 10 (07)
  • [24] Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
    Voth, Elida
    Solanky, Dipesh
    Loftus, Edward V., Jr.
    Pardi, Darrell S.
    Khanna, Sahil
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [25] Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease
    Abdehagh, Mohammad
    Azimirad, Masoumeh
    Houri, Hamidreza
    Nadalian, Banafsheh
    Azimirad, Fahimeh
    Olfatifar, Meysam
    Shoeibi, Ome Kolsoum Nasir
    Yadegar, Abbas
    Shahrokh, Shabnam
    Roshan, Mehran Mahdavi
    Aghdaei, Hamid Asadzadeh
    Zali, Mohammad Reza
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [26] Application of Procalcitonin for the Rapid Diagnosis of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease
    Xie, Shuhua
    Chen, Peisong
    Wang, Dong
    Jiang, Xiaobing
    Wu, Zhongwen
    Liao, Kang
    Liu, Min
    Zhang, Shihong
    Chen, Yili
    DIAGNOSTICS, 2022, 12 (12)
  • [27] Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease
    Mohammad Abdehagh
    Masoumeh Azimirad
    Hamidreza Houri
    Banafsheh Nadalian
    Fahimeh Azimirad
    Meysam Olfatifar
    Ome Kolsoum Nasir Shoeibi
    Abbas Yadegar
    Shabnam Shahrokh
    Mehran Mahdavi Roshan
    Hamid Asadzadeh Aghdaei
    Mohammad Reza Zali
    BMC Infectious Diseases, 21
  • [28] ASSOCIATION OF CLOSTRIDIOIDES DIFFICILE INFECTION WITH THE USE OF CORTICOSTEROIDS AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Gandhi, Mustafa
    Barffour, Maxwell
    Chela, Harleen
    Reznicek, Emily
    Karanja, Elizabeth
    Luton, Kevin
    Bosak, Emily
    Ghouri, Yezaz A.
    GASTROENTEROLOGY, 2023, 164 (06) : S643 - S643
  • [29] PCR CYCLE TIME AND CLOSTRIDIOIDES DIFFICILE INFECTION IN HOSPITALIZED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Moktan, Varun
    Jonica, Emily R.
    Li, Zhuo
    Hata, Jane
    Farraye, Francis A.
    GASTROENTEROLOGY, 2020, 158 (06) : S707 - S707
  • [30] Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease
    Gupta, Annu
    Wash, Christopher
    Wu, Yingxing
    Sorrentino, Dario
    Nguyen, Vu Q.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (02) : 547 - 553